Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Registre des résultats prospectifs de la fibrose pulmonaire idiopathique et de la maladie pulmonaire interstitielle (IPF/ILD-PRO)

9 novembre 2026 mis à jour par: Duke University

Registre des résultats prospectifs de la fibrose pulmonaire idiopathique (IPF-PRO) et de la maladie pulmonaire interstitielle fibrosante chronique avec phénotype progressif (IPF-PRO/ILD-PRO)

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

Aperçu de l'étude

Description détaillée

This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.

Type d'étude

Observationnel

Inscription (Estimé)

3000

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Alabama
      • Birmingham, Alabama, États-Unis, 35294
        • Recrutement
        • University of Alabama - Birmingham
        • Chercheur principal:
          • Tejaswini Kulkarni, MD
        • Contact:
    • Arizona
      • Tucson, Arizona, États-Unis, 85721
        • Recrutement
        • University of Arizona
        • Chercheur principal:
          • Sally A Suliman, MD
        • Contact:
    • California
      • Los Angeles, California, États-Unis, 90033
        • Recrutement
        • University of Southern California
        • Contact:
        • Chercheur principal:
          • Toby Maher, MD
      • Los Angeles, California, États-Unis, 90024
        • Recrutement
        • University of California - Los Angeles
        • Chercheur principal:
          • John Belperio, MD
        • Contact:
      • Stanford, California, États-Unis, 94305
        • Recrutement
        • Stanford University
        • Chercheur principal:
          • Rishi Raj, MD
        • Contact:
    • Colorado
      • Aurora, Colorado, États-Unis, 80045
        • Recrutement
        • University of Colorado
        • Chercheur principal:
          • Joyce Lee, MD
        • Contact:
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06520
        • Recrutement
        • Yale University
        • Chercheur principal:
          • Mridu Gulati, MD
        • Contact:
    • Florida
      • Gainesville, Florida, États-Unis, 32610-3175
      • Tampa, Florida, États-Unis, 33606
        • Recrutement
        • University of South Florida
        • Chercheur principal:
          • Jose D Herazo-Maya, MD
        • Contact:
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322
        • Recrutement
        • Emory University
        • Contact:
        • Chercheur principal:
          • Srihari Veeraraghavan, MD
      • Austell, Georgia, États-Unis, 30106
        • Recrutement
        • Piedmont Healthcare
        • Chercheur principal:
          • Amy Case, MD
        • Contact:
    • Illinois
      • Chicago, Illinois, États-Unis, 60637
        • Recrutement
        • University of Chicago
        • Chercheur principal:
          • Mary Strek, MD
        • Contact:
      • Evanston, Illinois, États-Unis, 60611
        • Recrutement
        • Northwestern University
        • Contact:
        • Chercheur principal:
          • Bradford Bemiss, MD
      • Maywood, Illinois, États-Unis, 60153
        • Recrutement
        • Loyola University Health System
        • Chercheur principal:
          • Daniel Dilling, MD
        • Contact:
    • Kansas
      • Kansas City, Kansas, États-Unis, 66160
        • Résilié
        • University of Kansas
    • Kentucky
      • Lexington, Kentucky, États-Unis, 40536
        • Recrutement
        • University of Kentucky
        • Chercheur principal:
          • Girish Nair, MD
        • Contact:
    • Louisiana
      • New Orleans, Louisiana, États-Unis, 70112
        • Recrutement
        • Tulane University
        • Chercheur principal:
          • Joe Lasky, MD
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • Actif, ne recrute pas
        • University of Michigan
      • Detroit, Michigan, États-Unis, 48202
        • Recrutement
        • Henry Ford Health
        • Contact:
        • Chercheur principal:
          • Asif Abdul Hameed, MD
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55455
        • Recrutement
        • University of Minnesota
        • Contact:
        • Chercheur principal:
          • Hyum Kim, MD
    • Mississippi
      • Jackson, Mississippi, États-Unis, 39216
        • Recrutement
        • University of Mississippi Medical Center
        • Chercheur principal:
          • Kimberly Dobbs, MD
        • Contact:
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • Recrutement
        • Washington University
        • Chercheur principal:
          • Tonya Russell, MD
        • Contact:
    • New York
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Weill Medical College of Cornell University
        • Chercheur principal:
          • Kerri Aronson, MD
        • Contact:
      • New York, New York, États-Unis, 10016
        • Actif, ne recrute pas
        • NYU Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27514
      • Durham, North Carolina, États-Unis, 27705
        • Recrutement
        • Duke University
        • Chercheur principal:
          • Lake Morrison, MD
        • Contact:
      • Greensboro, North Carolina, États-Unis, 27403
        • Recrutement
        • Pulmonix LLC
        • Chercheur principal:
          • Murali Ramaswamy, MD
        • Contact:
      • Wilmington, North Carolina, États-Unis, 28401
        • Résilié
        • PMG Research
      • Winston-Salem, North Carolina, États-Unis, 27157
        • Recrutement
        • Wake Forest Baptist Health
        • Contact:
        • Chercheur principal:
          • Andrew Namen, MD
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45267
        • Actif, ne recrute pas
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, États-Unis, 44195
        • Recrutement
        • Cleveland Clinic
        • Chercheur principal:
          • Brian Southern, MD
        • Contact:
      • Columbus, Ohio, États-Unis, 43210
        • Recrutement
        • The Ohio State University
        • Contact:
        • Chercheur principal:
          • John Odackal
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Recrutement
        • University of Oklahoma
        • Chercheur principal:
          • Jad Kebbe, MD
        • Contact:
    • Oregon
      • Portland, Oregon, États-Unis, 97220
        • Recrutement
        • Oregon Clinic
        • Chercheur principal:
          • David Hotchkin, MD
        • Contact:
    • Pennsylvania
      • Hershey, Pennsylvania, États-Unis, 17033
        • Recrutement
        • Penn State College of Medicine - Hershey
        • Chercheur principal:
          • Rebecca Bascom, MD
        • Contact:
      • Philadelphia, Pennsylvania, États-Unis, 19140
        • Recrutement
        • Temple University
        • Chercheur principal:
          • Rachel Criner, MD
        • Contact:
      • Philadelphia, Pennsylvania, États-Unis, 19144
    • South Carolina
      • Charleston, South Carolina, États-Unis, 29425
        • Recrutement
        • Medical University of South Carolina
        • Chercheur principal:
          • Timothy Whelan, MD
        • Contact:
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37232
        • Recrutement
        • Vanderbilt University
        • Contact:
        • Chercheur principal:
          • Justin Hewlett, MD
    • Texas
      • Dallas, Texas, États-Unis, 75235
        • Recrutement
        • University of Texas Southwestern
        • Chercheur principal:
          • John Fitzgerald, MD
        • Contact:
      • Dallas, Texas, États-Unis, 75246
        • Recrutement
        • Baylor University Medical Center at Dallas
        • Chercheur principal:
          • Yolanda Mageto, MD
        • Contact:
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • Baylor College of Medicine
        • Chercheur principal:
          • Ivan Rosas, MD
        • Contact:
      • Houston, Texas, États-Unis, 77030
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • The University of Texas Health Science Center At Houston
        • Chercheur principal:
          • Rodeo Abrencillo, MD
        • Contact:
    • Utah
      • Salt Lake City, Utah, États-Unis, 84108
        • Recrutement
        • University of Utah
        • Contact:
        • Chercheur principal:
          • Mary Beth Langer, MD
      • Salt Lake City, Utah, États-Unis, 84111
        • Recrutement
        • Intermountain Health
        • Contact:
        • Chercheur principal:
          • Erin Blackstock, MD
    • Vermont
      • Colchester, Vermont, États-Unis, 05446
        • Actif, ne recrute pas
        • University of Vermont Lung Center
    • Virginia
      • Charlottesville, Virginia, États-Unis, 22908
        • Actif, ne recrute pas
        • University from Virginia
      • Falls Church, Virginia, États-Unis, 22042-3307
        • Recrutement
        • Inova Health Care Services
        • Contact:
        • Chercheur principal:
          • Jared Wilkinson, MD
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Actif, ne recrute pas
        • The Medical College of Wisconsin

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

21 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.

La description

Inclusion Criteria:

  • Willing and able to provide informed consent

  • Established a new diagnosis (within 12 months) of IPF by the enrolling center.

  • Age 21 years or older, or

  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:

    • Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.

    • Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):

      • decline in FVC % predicted (% pred) based on ≥10% relative decline
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
      • decline in DLCO % pred based on≥ 10% relative decline
      • worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.

The relative decline for FVC % predicted is calculated using the formula:

Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.

The relative decline for DLCO % predicted is calculated using the formula:

Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening

Exclusion Criteria:

  • Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
  • For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry

Subjects with a non-IPF ILD diagnosis

Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

New Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Délai: End of Study (3 years after last patient will be enrolled)

Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.

End of Study (3 years after last patient will be enrolled)
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Délai: End of Study (3 years after last patient will be enrolled)

Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD

End of Study (3 years after last patient will be enrolled)
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Délai: End of Study (3 years after last patient will be enrolled)

Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL).

End of Study (3 years after last patient will be enrolled)
Blood samples for future research.
Délai: End of Study (3 years after last patient will be enrolled)

Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions.

End of Study (3 years after last patient will be enrolled)
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Délai: End of Study (3 years after last patient will be enrolled)

Collect longitudinal HRCT images for future research

End of Study (3 years after last patient will be enrolled)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Data on management practices compared to existing guidelines.
Délai: End of Study (3 years after last patient will be enrolled)

Compare disease-specific management practices with existing guidelines.

End of Study (3 years after last patient will be enrolled)
Data on center-specific practices on outcomes.
Délai: End of Study (3 years after last patient will be enrolled)

Determine the influence of center-specific practices on patient outcomes.

End of Study (3 years after last patient will be enrolled)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chercheur principal: Scott Palmer, MD, Duke Clinical Research Institute, Duke University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 juin 2014

Achèvement primaire (Estimé)

1 janvier 2028

Achèvement de l'étude (Estimé)

1 janvier 2031

Dates d'inscription aux études

Première soumission

31 juillet 2013

Première soumission répondant aux critères de contrôle qualité

1 août 2013

Première publication (Estimé)

5 août 2013

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 juillet 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner